Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients
| Autor: | Yale B. Mitchel, Evan A. Stein, Stuart R. Weiss, Helmut G. Schrott, Michael Stepanavage, Harold E. Bays, Carlos A. Dujovne, Michael Melino, Adrian S. Dobs, Michael H. Davidson |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Ldl cholesterol
medicine.medical_specialty Chemotherapy business.industry Cholesterol medicine.medical_treatment Gastroenterology Confidence interval Pharmacological treatment chemistry.chemical_compound Endocrinology chemistry Simvastatin Internal medicine Cardiology Medicine lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business National Cholesterol Education Program Lipoprotein medicine.drug |
| Zdroj: | The American Journal of Cardiology. 82:311-316 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(98)00421-4 |
| Popis: | This randomized, multicenter, double-blind parallel-group study was performed to evaluate the lipid-altering efficacy and safety of simvastatin 80 mg/day, a dose twice the current maximum recommended dose. At 20 centers in the United States, 521 male and female hypercholesterolemic patients were randomly assigned in a ratio of 2:3 to receive simvastatin 40 or 80 mg once daily, respectively, for 24 weeks in conjunction with a lipid-lowering diet. Patients met National Cholesterol Education Program (NCEP) low-density lipoprotein (LDL) cholesterol criteria for pharmacologic treatment. The mean percentage reductions (95% confidence intervals) from baseline in LDL cholesterol averaged at weeks 18 and 24 were 38% (−40 to −36) and 46% (−47 to −45) for the 40- and 80-mg groups, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect